SCHEMBL2802827

SCHEMBL2802827

COc1ccc(S(=O)(=O)N2CCc3c(cnc4[nH]ncc34)C2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.56
CYP2C19 P33261 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
PKM P14618 3/20 0.47
GPBAR1 Q8TDU6 1/20 0.46
HTR6 P50406 2/20 0.46
LMNA P02545 1/20 0.45
MAP4K1 Q92918 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43
AKR1C3 P42330 2/20 0.43
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806192 0.92 CYP3A4 (0.46) CYP3A4CYP2C19SMN1; SMN2NPSR1PKM
SCHEMBL2802910 0.87 PKM (0.52) SMN1; SMN2PKMLMNAALDH1A1KDM4E
SCHEMBL2804355 0.85 AKR1C3 (0.47) CYP3A4CYP2C19SMN1; SMN2NPSR1PKM
SCHEMBL2806833 0.85 KMT2A (0.49) PKMALDH1A1KDM4ETSHRMAPT
SCHEMBL2804301 0.84 GAA (0.50) SMN1; SMN2LMNAALDH1A1USP2TSHR
SCHEMBL2804811 0.83 PKM (0.44) CYP2C19PKMALDH1A1TSHRPOLB
SCHEMBL2802935 0.83 MAPT (0.41) SMN1; SMN2PKMHTR6LMNAALDH1A1
SCHEMBL2805746 0.83 RAB9A (0.41) SMN1; SMN2HTR6LMNAAKR1C3POLB
SCHEMBL2805569 0.83 KMT2A (0.43) MAPTPOLB
SCHEMBL2805945 0.83 MCOLN3 (0.48) CYP3A4CYP2C19SMN1; SMN2NPSR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 CYP3A4 811/4885CYP2C19 945/4885SMN1; SMN2 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.